These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 32526966)

  • 1. Polymyxins-Curcumin Combination Antimicrobial Therapy: Safety Implications and Efficacy for Infection Treatment.
    Dai C; Wang Y; Sharma G; Shen J; Velkov T; Xiao X
    Antioxidants (Basel); 2020 Jun; 9(6):. PubMed ID: 32526966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug.
    Krishnamurthy M; Lemmon MM; Falcinelli EM; Sandy RA; Dootz JN; Mott TM; Rajamani S; Schaecher KE; Duplantier AJ; Panchal RG
    Infect Drug Resist; 2019; 12():1393-1405. PubMed ID: 31239720
    [No Abstract]   [Full Text] [Related]  

  • 3. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of polymyxin antibiotics.
    Kelesidis T; Falagas ME
    Expert Opin Drug Saf; 2015; 14(11):1687-701. PubMed ID: 26365594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention.
    Dai C; Xiao X; Li J; Ciccotosto GD; Cappai R; Tang S; Schneider-Futschik EK; Hoyer D; Velkov T; Shen J
    ACS Chem Neurosci; 2019 Jan; 10(1):120-131. PubMed ID: 30362702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins.
    Wagenlehner F; Lucenteforte E; Pea F; Soriano A; Tavoschi L; Steele VR; Henriksen AS; Longshaw C; Manissero D; Pecini R; Pogue JM
    Clin Microbiol Infect; 2021 Jan; ():. PubMed ID: 33359542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.
    Vaara M
    Med Res Rev; 2018 Sep; 38(5):1661-1673. PubMed ID: 29485690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Combinations of Polymyxins with Other Antibiotics.
    Bergen PJ; Smith NM; Bedard TB; Bulman ZP; Cha R; Tsuji BT
    Adv Exp Med Biol; 2019; 1145():251-288. PubMed ID: 31364082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic combinations of polymyxins.
    Lenhard JR; Nation RL; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.
    Azad MAK; Sivanesan S; Wang J; Chen K; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.
    Roberts KD; Azad MA; Wang J; Horne AS; Thompson PE; Nation RL; Velkov T; Li J
    ACS Infect Dis; 2015 Nov; 1(11):568-575. PubMed ID: 27525307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agents of Last Resort: Polymyxin Resistance.
    Kaye KS; Pogue JM; Tran TB; Nation RL; Li J
    Infect Dis Clin North Am; 2016 Jun; 30(2):391-414. PubMed ID: 27208765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the ATP Synthase Eliminates the Intrinsic Resistance of
    Vestergaard M; Nøhr-Meldgaard K; Bojer MS; Krogsgård Nielsen C; Meyer RL; Slavetinsky C; Peschel A; Ingmer H
    mBio; 2017 Sep; 8(5):. PubMed ID: 28874470
    [No Abstract]   [Full Text] [Related]  

  • 17. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin Combinations Combat
    Bulman ZP; Chen L; Walsh TJ; Satlin MJ; Qian Y; Bulitta JB; Peloquin CA; Holden PN; Nation RL; Li J; Kreiswirth BN; Tsuji BT
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of colistin induced nephrotoxicity: a review of preclinical and clinical data.
    Jafari F; Elyasi S
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1113-1131. PubMed ID: 34015235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.